Neoadjuvant Chemotherapy with Cetuximab for Locally Advanced Penile Cancer

Jiyan Liu,Wuxia Luo,He Jian,Xiang Li

DOI: https://doi.org/10.4103/0973-1482.151945

2015-01-01

Abstract:Sir, Penile squamous cell carcinoma (SCC) is a rare malignancy.[1] Neoadjuvant chemotherapy represents the standard of treatment for patients with locally advanced penile SCC.[2] Recently, our previous study noted that the overexpression of epidermal growth factor receptor (EGFR) was common and mutations of KRAS and BRAF were rare in penile SCC, which suggested anti-EGFR antibody might be potentially beneficial to penile SCC.[3] Here, we describe a patient with locally advanced penile SCC using neoadjuvant chemotherapy with cetuximab (an anti-EGFR antibody). In November 2013, a 68-year-old man, complaining about masses in his penis and groin, was diagnosed as penile SCC by pathological examination after fine-needle aspiration. Then, the patient received the total penectomy in the local hospital. However, the masses in his groin grew rapidly with secondary bacterial infection [Figure 1a]. He was referred to our hospital for further treatment in December 2013. Computed tomography showed enlarged soft tissue shadows in his bilateral inguinal region [Figure 2a and b]. KRAS and BRAF gene status analysis of the tumor showed wild types. Obviously, the tumor was considered unresectable. Then the patient started neoadjuvant therapy with cetuximab 800 mg on day 1 plus chemotherapy with paclitaxel 210 mg on day 1 and cisplatin 30 mg on day 1-3 every 2 weeks, and anti-infection treatment was also performed. After two chemotherapeutic cycles, his tumor achieved a partial response (PR) with a significant reduction in masses size and complete control of the infection [Figure 2c and d]. After completion of the fourth course of chemotherapy, the swollen lymph nodes shrinked obviously [Figure 1b]. Then he successfully underwent bilateral inguinal lymph node dissection in April 2014. Histopathological examination revealed that cancerous metastases were found in six lymph nodes. After 2 months recurrence-free time, unfortunately, the patient suffered a tumor recurrence in his right groin.Figure 1: (a) Pink cutaneous nodular lesions in the groin were red and swollen before cetuximab and chemotherapy. (b) The swollen nodular lesion regression was obvious after cetuximab and chemotherapyFigure 2: Computed tomography showing enlarged tissue shadows in the right (a) and left (b) groin region before cetuximab and chemotherapy. Two cycles later, partial response was achieved with a significant reduction in masses size (c and d)Although long disease-free time was not achieved in this case, a PR was achieved and bilateral inguinal lymph node dissection was completed. The good clinical response to cetuximab-containing chemotherapy followed by successful radical surgery suggested potential application of cetuximab in neoadjuvant therapy for locally advanced penile SCC. As we know, cisplatin-containing chemotherapy is now considered the first choice in neoadjuvant setting for advanced penile cancer; however, the prognosis of advanced penile SCC is poor.[24] The chemotherapy regimen of three-drug combination likely leads to greater response, but more adverse reactions. In the prospective trial of neoadjuvant chemotherapy for advanced penile SCC (paclitaxel, cisplatin, and ifosfamide), a number of grades 3 and 4 adverse events were occurred.[2] Theoretically, replacing a kind of chemotherapy drug with cetuximab may reduce the overlap of possible adverse effects among chemotherapy drugs. In this case, mild acne-like rashes were observed due to cetuximab-related toxicity and the regimen was well-tolerated. Given the rarity of the disease, the realization of a prospective trial will be difficult. The experience of treatment for penile SCC should be gathered case by case. Future investigations of anti-EGFR antibody in neoadjuvant setting for locally advanced penile SCC are warranted.